Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naïve locally advanced or metastatic renal cell carcinoma
2009-014249-10Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pazopanib and sunitinib in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by GSK. Primary endpoint: Patient preference. Started Feb 2010; status: completed.
02
Drugs
pazopanibsunitinib
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2009-014249-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014249-10.